Journal
CURRENT STEM CELL REPORTS
Volume 2, Issue 2, Pages 168-173Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s40778-016-0044-6
Keywords
Mesenchymal stem cells; Immune suppression; Multiple sclerosis; EAE
Categories
Funding
- NICHD NIH HHS [U54 HD090257] Funding Source: Medline
- NINDS NIH HHS [R01 NS030800] Funding Source: Medline
Ask authors/readers for more resources
The utilization of mesenchymal stem cells (also known as mesenchymal stromal cells (MSCs)) as a cell-based therapy for diseases that have ongoing inflammatory damage has become increasingly available. Our understanding of the cell biology of MSCs is still incomplete. However, as a result of increasing numbers of preclinical and clinical studies, general themes are emerging. The capacity of MSCs to reduce disease burden is largely associated with their ability to modulate the activity of the host immune responses rather than to contribute directly to tissue regeneration. As a result, they have significant potential in the treatment of chronic inflammatory disease regardless of the affected tissue. For example, MSC-based therapies have been developed in the context of diseases as diverse as rheumatoid arthritis and multiple sclerosis. Here, we discuss some of the principles that link these conditions and the aspects of MSC biology that contribute to their use as a therapy for chronic inflammatory conditions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available